NCT05102825 Imaging Measures of Respiratory Health Registry
| NCT ID | NCT05102825 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Respiratory Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-06-11 |
| Primary Completion | 2045-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-06-11 with a primary completion date of 2045-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, observational cohort registry that aims to collect data on pulmonary structure and function in healthy people and those with respiratory disease, using structural and functional pulmonary 1H-MRI and hyperpolarized 129Xe-MRI. Outcome measures generated from MRI may include but are not limited to measures of regional ventilation, pulmonary microarchitecture, and regional gas exchange. Additionally, one of the goals of the registry is to facilitate the development of novel image analysis techniques that have not yet been invented. These data will be stored along with demographic data, clinical data, and pulmonary function testing (PFT) data. This is an open registry. Eligible local and international investigators/institutions can apply for access.
Eligibility Criteria
Respiratory Disease Inclusion Criteria: 1. Physician-diagnosed lung disease - based on a diagnosis made by a treating staff physician and confirmed by the principal investigator. 2. Age 0-99 years. 3. Informed consent by participant, parent, or legal guardian 4. In the opinion of the Investigator, the participant will likely be able to perform maneuvers to obtain technically acceptable pulmonary XeMRI images. Exclusion Criteria: 1. Physical findings at screening that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the research data. 2. Requirement of supplementary oxygen to maintain an oxygen saturation above 95%. 3. Failed MRI screening form. 4. History of claustrophobia. 5. Known current pregnancy or lactation. Healthy Inclusion Criteria: 1. Age 0-99 years 2. Informed consent by participant, parent, or legal guardian 3. In the opinion of the Investigator, the participant will likely be able to perform maneuvers to obtain technically acceptable pulmonary MRI images. Exclusion Criteria 1. Physician-diagnosed lung disease. 2. Failed MRI screening form. 3. History of claustrophobia. 4. Physical findings at screening that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the research data. 5. Known current pregnancy or lactation.
Contact & Investigator
Jonathan Rayment, MDCM, MSc
PRINCIPAL INVESTIGATOR
University of British Columbia
Frequently Asked Questions
Who can join the NCT05102825 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 99 Years, studying Respiratory Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05102825 currently recruiting?
Yes, NCT05102825 is actively recruiting participants. Contact the research team at Rodrigo.Sandoval@bcchr.ca for enrollment information.
Where is the NCT05102825 trial being conducted?
This trial is being conducted at Vancouver, Canada, Vancouver, Canada.
Who is sponsoring the NCT05102825 clinical trial?
NCT05102825 is sponsored by University of British Columbia. The principal investigator is Jonathan Rayment, MDCM, MSc at University of British Columbia. The trial plans to enroll 1,000 participants.